Biotech is dominating the (very) early 2026 deals market.
Biotech domina i deal 2026 con 25/59 venture (7 round >$100M), reversal dal tech-first order. Convergenza biotech-tech ridefinisce allocazione venture: CTO devono prepararsi a shift competenze verso stack biotech-compliant.
Add Axios as your preferred source to
see more of our stories on Google.
Illustration: Annelise Capossela/Axios
Biotech is dominating the (very) early 2026 deals market, whether that be startup fundings, IPOs, or mergers.
Why it matters: This is a reversal of the usual order, in which biotech plays distant second cousin to the sorts of tech that don't need FDA approval.
Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in…
Catalyst is already the fourth biotech acquisition this month, continuing an acceleration of bigger-ticket deals that’s put 2026…
Biopharma dealmaking rebounds in Q2 2026: M&A nears $80B and licensing/R&D alliances hit a 5-year record $83B, per DealForma.
Though funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that small…
Pharmaceutical companies are hungry to make deals, and they’re making more than they have in years.
The biotech stock rally that began in April 2025 has not stopped, and if anything, has accelerated.
